1. Generics Bulletin
  2. >>Legal & IP

Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?

Debate Over Need For, Impact Of Plan

 
• By Anju Ghangurde

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

IPR
Will views on IPR waiver for COVID-19 vaccines align? • Source: Alamy

The US government’s decision to back the waiver of intellectual property protections for COVID-19 vaccines is seen as momentous. But some legal experts note that the text-based negotiations to follow are not going to be easy and will likely require heavy-duty diplomatic efforts to align views, if at all.

Generics Bulletin sister publication Scrip reached out to a cross-section of IP experts on the long road ahead and whether the scope of the proposed waiver could be a sticking point given, for instance, the wider promise of mRNA technology in areas beyond vaccines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.